Immunothearpy for the Treatment of Multiple Myeloma

Abstract

Expected survival rates are rapidly increasing for myeloma but the relapse burden is the major obstacle to obtaining long-term remission and maybe even cure. Like many other hematological malignancies immunotherapies emerged as a very promising approach and new studies are eagerly awaited. Despite marked success with many new agents’ safety remains a major concern as fatal CRS and ICANS still endanger the therapy process. With the advent of new safer and cheaper therapeutics in myeloma, standard approaches will completely replace by immunotherapeutics and cellular therapies in the near future.